# OnCo record global-access-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/global-access-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "global-access-roadmap" ;
  schema:name "Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation"@en ;
  schema:description "Seven in ten cancer deaths happen in countries with almost no cancer care, and even rich systems cannot afford every new drug. The roadmap is the set of levers that already work, from generics and biosimilars to trials that cut the dose, and the ones being built: regulators trusting each other's reviews, pooled purchasing, and drugs and cell therapies made where patients live."@en ;
  schema:url <https://onco.cc/roadmaps/global-access-roadmap/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://onco.cc/costs/>, <https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists>, <https://doi.org/10.1016/S1470-2045(14)70117-2>, <https://doi.org/10.1200/JCO.22.01015> ;
  onco:related <https://onco.cc/collections/nice-guidance/>, <https://onco.cc/key-papers/paper-pramesh-ncg-pooled-procurement-2023/>, <https://onco.cc/key-papers/paper-patil-low-dose-nivolumab-jco-2023/>, <https://onco.cc/collections/csco-guidelines/>, <https://onco.cc/collections/esmo-guidelines/>, <https://onco.cc/collections/src-nice-ta/>, <https://onco.cc/ideas/idea-reg-orbis-work-sharing/>, <https://onco.cc/ideas/idea-reg-reliance-90-day-lmic/>, <https://onco.cc/ideas/idea-acc-biosimilar-prequalification-pool/>, <https://onco.cc/ideas/idea-reg-pd1-biosimilar-advance-commitment/>, <https://onco.cc/ideas/idea-reg-biosimilar-no-efficacy-trial/>, <https://onco.cc/ideas/idea-reg-patent-pool-oncology-eml/>, <https://onco.cc/ideas/idea-acc-eml-listing-price-commitments/>, <https://onco.cc/ideas/idea-reg-tiered-pricing-for-exclusivity/>, <https://onco.cc/ideas/idea-acc-pooled-procurement-radiotherapy/>, <https://onco.cc/ideas/idea-acc-linac-uptime-contracts/>, <https://onco.cc/ideas/idea-acc-frugal-hdr-brachytherapy/>, <https://onco.cc/ideas/idea-acc-hypofractionation-default-lmic/>, <https://onco.cc/ideas/idea-reg-lmic-public-cart-manufacturing/>, <https://onco.cc/ideas/idea-fund-public-car-t-manufacturing/>, <https://onco.cc/ideas/idea-fund-global-cancer-fund/>, <https://onco.cc/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/>, <https://onco.cc/ideas/idea-reg-metronomic-lmic-phase3-to-label/>, <https://onco.cc/ideas/idea-acc-metronomic-lmic-platform-trial/>, <https://onco.cc/ideas/idea-reg-price-anchored-to-mcbs/>, <https://onco.cc/ideas/idea-reg-indication-specific-pricing/>, <https://onco.cc/ideas/idea-reg-public-deescalation-trials-for-cost/>, <https://onco.cc/ideas/idea-reg-biosimilar-first-default-switching/>, <https://onco.cc/ideas/idea-reg-nonprofit-generic-chemo-manufacturer/>, <https://onco.cc/ideas/idea-reg-financial-toxicity-vital-sign/>, <https://onco.cc/ideas/idea-cost-shorter-course-trials/>, <https://onco.cc/ideas/idea-reg-middle-income-negotiation-bloc/>, <https://onco.cc/ideas/idea-acc-community-health-workers-oncology/>, <https://onco.cc/ideas/idea-acc-echo-tele-mentoring-oncology/>, <https://onco.cc/ideas/idea-acc-remote-planning-hubs/>, <https://onco.cc/ideas/idea-acc-balanced-opioid-policy-reform/>, <https://onco.cc/ideas/idea-acc-registries-as-aid-condition/>, <https://onco.cc/ideas/idea-prev-lmic-five-cancer-methylation-test/>, <https://onco.cc/ideas/idea-fund-lmic-burden-match/>, <https://onco.cc/ideas/idea-tr1-lmic-sites-in-pivotal-trials/>, <https://onco.cc/ideas/idea-acc-hpv-self-sample-same-day-ablation/>, <https://onco.cc/roadmaps/prevention-roadmap/>, <https://onco.cc/roadmaps/chemotherapy-roadmap/>, <https://onco.cc/roadmaps/radiation-roadmap/>, <https://onco.cc/roadmaps/trial-modernisation-roadmap/> ;
  onco:technologies <https://onco.cc/technologies/global-oncology-access/>, <https://onco.cc/technologies/generic-drug-shortage-response/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/hpv-testing/>, <https://onco.cc/technologies/precancer-ablation/>, <https://onco.cc/technologies/telemedicine-teleoncology/>, <https://onco.cc/technologies/oral-visual-screening/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-biosimilars/>, <https://onco.cc/drugs/talicabtagene-autoleucel/>, <https://onco.cc/drugs/varnimcabtagene-autoleucel/>, <https://onco.cc/drugs/cervavac/>, <https://onco.cc/drugs/sintilimab/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/relmacabtagene-autoleucel/>, <https://onco.cc/drugs/trastuzumab-rezetecan/> ;
  onco:companies <https://onco.cc/companies/cipla/>, <https://onco.cc/companies/natco/>, <https://onco.cc/companies/dr-reddys/>, <https://onco.cc/companies/sun-pharma/>, <https://onco.cc/companies/biocon/>, <https://onco.cc/companies/biocon-biologics/>, <https://onco.cc/companies/intas/>, <https://onco.cc/companies/zydus/>, <https://onco.cc/companies/immunoact/>, <https://onco.cc/companies/immuneel/>, <https://onco.cc/companies/serum-institute-of-india/>, <https://onco.cc/companies/hengrui/>, <https://onco.cc/companies/innovent/>, <https://onco.cc/companies/junshi/> ;
  onco:institutions <https://onco.cc/institutions/who/>, <https://onco.cc/institutions/uicc/>, <https://onco.cc/institutions/tata-memorial/>, <https://onco.cc/institutions/national-cancer-grid/>, <https://onco.cc/institutions/tata-trusts/>, <https://onco.cc/institutions/nhsa/>, <https://onco.cc/institutions/fda-oce/>, <https://onco.cc/institutions/ema/>, <https://onco.cc/institutions/iarc/> ;
  onco:terms <https://onco.cc/terms/biosimilar/>, <https://onco.cc/terms/who-essential-medicines/>, <https://onco.cc/terms/project-orbis/>, <https://onco.cc/terms/hta/>, <https://onco.cc/terms/hypofractionation/> ;
  onco:trials <https://onco.cc/trials/low-dose-nivolumab-tmh/>, <https://onco.cc/trials/metronomic-vs-cisplatin-tmh/>, <https://onco.cc/trials/metro-plus-varanasi/>, <https://onco.cc/trials/progesterone-preop-tmh/>, <https://onco.cc/trials/elective-neck-dissection-tmh/>, <https://onco.cc/trials/interlace/>, <https://onco.cc/trials/persephone/>, <https://onco.cc/trials/talicel-phase-1-2/>, <https://onco.cc/trials/imagine-varnimcabtagene/>, <https://onco.cc/trials/orient-11/>, <https://onco.cc/trials/harmoni-2/>, <https://onco.cc/trials/reliance/>, <https://onco.cc/trials/osmanabad-hpv-screening/>, <https://onco.cc/trials/kerala-oral-screening/>, <https://onco.cc/trials/mumbai-via-screening/>, <https://onco.cc/trials/iarc-india-hpv-dose-study/>, <https://onco.cc/trials/ken-she/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-regulatory-fragmentation/>, <https://onco.cc/bottlenecks/b-workforce/>, <https://onco.cc/bottlenecks/b-palliative/>, <https://onco.cc/bottlenecks/b-generic-repurposing/>, <https://onco.cc/bottlenecks/b-trial-diversity/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-pramesh-lancet-oncol/> .